The White House has withdrawn Dr. Heidi Overton’s nomination for FDA commissioner just a day before a Senate committee vote.
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania ...
Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo ...
Pharmaceutical Executive spoke with Ankit Jain, CEO and founder of Infinitus, about how agentic AI models are being deployed ...
Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its ...
White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in ...
Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers ...
New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk ...
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, ...
Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica ...
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results